These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34389513)

  • 1. Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus.
    Abushanab D; Liew D; Marquina C; Al-Badriyeh D; Ademi Z
    Endocr Pract; 2022 Jan; 28(1):16-24. PubMed ID: 34389513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis.
    Abushanab D; Al-Badriyeh D; Liew D; Ademi Z
    Curr Probl Cardiol; 2022 Jun; 47(6):100852. PubMed ID: 33992426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes.
    Chin KL; Ofori-Asenso R; Si S; Hird TR; Magliano DJ; Zoungas S; Liew D
    Sci Rep; 2019 Mar; 9(1):3256. PubMed ID: 30824788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.
    Reifsnider O; Kansal A; Pimple P; Aponte-Ribero V; Brand S; Shetty S
    Diabetes Obes Metab; 2021 Mar; 23(3):791-799. PubMed ID: 33236481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
    Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
    Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
    Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.
    Reifsnider OS; Pimple P; Brand S; Bergrath Washington E; Shetty S; Desai NR
    Diabetes Obes Metab; 2022 Apr; 24(4):652-661. PubMed ID: 34910356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark.
    Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
    J Comp Eff Res; 2022 Jan; 11(1):29-37. PubMed ID: 34841893
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
    Nguyen E; Coleman CI; Nair S; Weeda ER
    J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.
    Erhardt W; Bergenheim K; Duprat-Lomon I; McEwan P
    Clin Drug Investig; 2012 Mar; 32(3):189-202. PubMed ID: 22292415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China.
    Salem A; Men P; Ramos M; Zhang YJ; Ustyugova A; Lamotte M
    J Comp Eff Res; 2021 Apr; 10(6):469-480. PubMed ID: 33576249
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.